MedMira Inc. (MMIRF)
USD 0.02
(0.0%)
USD 0.02
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 9.25 Million CAD | 12.01% |
| 2022 | 8.26 Million CAD | -40.27% |
| 2021 | 13.83 Million CAD | 20.25% |
| 2020 | 11.5 Million CAD | 35.06% |
| 2019 | 8.52 Million CAD | 12.37% |
| 2018 | 7.58 Million CAD | 11.8% |
| 2017 | 6.78 Million CAD | 9.35% |
| 2016 | 6.2 Million CAD | -7.32% |
| 2015 | 6.69 Million CAD | 10.48% |
| 2014 | 6.05 Million CAD | -11.6% |
| 2013 | 6.85 Million CAD | 37.18% |
| 2012 | 4.99 Million CAD | -63.34% |
| 2011 | 13.62 Million CAD | 6.84% |
| 2010 | 12.75 Million CAD | 8.79% |
| 2009 | 11.72 Million CAD | 9.44% |
| 2008 | 10.71 Million CAD | 4.74% |
| 2007 | 10.22 Million CAD | 8.41% |
| 2006 | 9.43 Million CAD | 15.91% |
| 2005 | 8.13 Million CAD | 75.65% |
| 2004 | 4.63 Million CAD | 179.43% |
| 2003 | 1.65 Million CAD | -80.38% |
| 2002 | 8.45 Million CAD | 58983.77% |
| 2001 | -14.35 Thousand CAD | -100.12% |
| 2000 | 11.97 Million CAD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q3 | 5.94 Million CAD | -26.4% |
| 2024 Q1 | 8.36 Million CAD | -9.63% |
| 2024 Q2 | 8.07 Million CAD | -3.51% |
| 2023 Q2 | 8.75 Million CAD | 1.69% |
| 2023 Q1 | 8.61 Million CAD | 4.21% |
| 2023 FY | 9.25 Million CAD | 12.01% |
| 2023 Q3 | 9.23 Million CAD | 5.47% |
| 2023 Q4 | 9.25 Million CAD | 0.22% |
| 2022 Q3 | 7.95 Million CAD | 6.63% |
| 2022 Q1 | 10.5 Million CAD | -24.08% |
| 2022 FY | 8.26 Million CAD | -40.27% |
| 2022 Q2 | 7.46 Million CAD | -28.97% |
| 2022 Q4 | 8.26 Million CAD | 3.87% |
| 2021 Q4 | 13.83 Million CAD | 20.26% |
| 2021 Q1 | 11.22 Million CAD | -2.46% |
| 2021 Q2 | 11.6 Million CAD | 3.4% |
| 2021 FY | 13.83 Million CAD | 20.25% |
| 2021 Q3 | 11.5 Million CAD | -0.86% |
| 2020 Q4 | 11.5 Million CAD | -0.24% |
| 2020 Q1 | 13.83 Million CAD | 62.33% |
| 2020 Q2 | 11.66 Million CAD | -15.67% |
| 2020 Q3 | 11.53 Million CAD | -1.1% |
| 2020 FY | 11.5 Million CAD | 35.06% |
| 2019 Q4 | 8.52 Million CAD | 3.3% |
| 2019 Q1 | 7.97 Million CAD | 5.22% |
| 2019 FY | 8.52 Million CAD | 12.37% |
| 2019 Q2 | 8.19 Million CAD | 2.75% |
| 2019 Q3 | 8.24 Million CAD | 0.61% |
| 2018 Q3 | 7.53 Million CAD | 2.1% |
| 2018 Q4 | 7.58 Million CAD | 0.59% |
| 2018 FY | 7.58 Million CAD | 11.8% |
| 2018 Q1 | 7.2 Million CAD | 6.15% |
| 2018 Q2 | 7.38 Million CAD | 2.55% |
| 2017 Q1 | 6.09 Million CAD | -1.72% |
| 2017 Q4 | 6.78 Million CAD | 3.59% |
| 2017 Q3 | 6.54 Million CAD | 6.89% |
| 2017 Q2 | 6.12 Million CAD | 0.47% |
| 2017 FY | 6.78 Million CAD | 9.35% |
| 2016 FY | 6.2 Million CAD | -7.32% |
| 2016 Q4 | 6.2 Million CAD | 7.64% |
| 2016 Q1 | 3.3 Million CAD | -50.55% |
| 2016 Q3 | 5.76 Million CAD | 27.6% |
| 2016 Q2 | 4.51 Million CAD | 36.46% |
| 2015 Q4 | 6.69 Million CAD | 11.26% |
| 2015 FY | 6.69 Million CAD | 10.48% |
| 2015 Q2 | 6.5 Million CAD | 10.55% |
| 2015 Q1 | 5.88 Million CAD | -2.87% |
| 2015 Q3 | 6.01 Million CAD | -7.52% |
| 2014 FY | 6.05 Million CAD | -11.6% |
| 2014 Q4 | 6.05 Million CAD | 10.19% |
| 2014 Q3 | 5.49 Million CAD | 49.06% |
| 2014 Q2 | 3.68 Million CAD | 107.38% |
| 2014 Q1 | 1.77 Million CAD | -74.05% |
| 2013 Q1 | 6.52 Million CAD | 30.51% |
| 2013 FY | 6.85 Million CAD | 37.18% |
| 2013 Q4 | 6.85 Million CAD | 9.37% |
| 2013 Q3 | 6.26 Million CAD | 11.56% |
| 2013 Q2 | 5.61 Million CAD | -13.85% |
| 2012 Q3 | 17.01 Million CAD | -0.29% |
| 2012 Q2 | 17.06 Million CAD | 17.9% |
| 2012 Q1 | 14.47 Million CAD | 6.23% |
| 2012 FY | 4.99 Million CAD | -63.34% |
| 2012 Q4 | 4.99 Million CAD | -70.64% |
| 2011 Q3 | 14.71 Million CAD | 1.05% |
| 2011 Q1 | 13.29 Million CAD | 4.22% |
| 2011 FY | 13.62 Million CAD | 6.84% |
| 2011 Q4 | 13.62 Million CAD | -7.4% |
| 2011 Q2 | 14.56 Million CAD | 9.55% |
| 2010 Q1 | 6.8 Million CAD | -42.0% |
| 2010 Q2 | 9.07 Million CAD | 33.47% |
| 2010 Q3 | 11.91 Million CAD | 31.24% |
| 2010 Q4 | 12.75 Million CAD | 7.07% |
| 2010 FY | 12.75 Million CAD | 8.79% |
| 2009 Q3 | 11.87 Million CAD | -2.4% |
| 2009 FY | 11.72 Million CAD | 9.44% |
| 2009 Q1 | 11.22 Million CAD | 4.81% |
| 2009 Q2 | 12.16 Million CAD | 8.33% |
| 2009 Q4 | 11.72 Million CAD | -1.25% |
| 2008 Q4 | 10.71 Million CAD | 7.05% |
| 2008 FY | 10.71 Million CAD | 4.74% |
| 2008 Q3 | 10 Million CAD | -2.12% |
| 2008 Q2 | 10.22 Million CAD | 4.91% |
| 2008 Q1 | 9.74 Million CAD | -4.71% |
| 2007 Q3 | 10.56 Million CAD | 0.06% |
| 2007 FY | 10.22 Million CAD | 8.41% |
| 2007 Q2 | 10.56 Million CAD | -51.64% |
| 2007 Q4 | 10.22 Million CAD | -3.23% |
| 2007 Q1 | 21.84 Million CAD | 131.49% |
| 2006 Q3 | 8.26 Million CAD | -25.86% |
| 2006 Q4 | 9.43 Million CAD | 14.21% |
| 2006 FY | 9.43 Million CAD | 15.91% |
| 2006 Q1 | 10.59 Million CAD | 30.17% |
| 2006 Q2 | 11.14 Million CAD | 5.16% |
| 2005 Q1 | 6.27 Million CAD | 35.48% |
| 2005 FY | 8.13 Million CAD | 75.65% |
| 2005 Q3 | 7.05 Million CAD | 5.56% |
| 2005 Q4 | 8.13 Million CAD | 15.45% |
| 2005 Q2 | 6.67 Million CAD | 6.37% |
| 2004 FY | 4.63 Million CAD | 179.43% |
| 2004 Q1 | 1.97 Million CAD | 19.3% |
| 2004 Q4 | 4.63 Million CAD | 38.94% |
| 2004 Q2 | 2.26 Million CAD | 14.35% |
| 2004 Q3 | 3.33 Million CAD | 47.43% |
| 2003 Q4 | 1.65 Million CAD | -82.43% |
| 2003 FY | 1.65 Million CAD | -80.38% |
| 2003 Q1 | 9.06 Million CAD | 7.29% |
| 2003 Q2 | 8.84 Million CAD | -2.5% |
| 2003 Q3 | 9.44 Million CAD | 6.78% |
| 2002 Q3 | 1.37 Million CAD | 86.43% |
| 2002 FY | 8.45 Million CAD | 58983.77% |
| 2002 Q4 | 8.45 Million CAD | 516.5% |
| 2002 Q1 | 309.19 Thousand CAD | 0.0% |
| 2002 Q2 | 735.27 Thousand CAD | 137.8% |
| 2001 FY | -14.35 Thousand CAD | -100.12% |
| 2000 FY | 11.97 Million CAD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1310.00 USD | 706819.389% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 246.847% |
| Neon Bloom, Inc. | 622.36 Thousand USD | -1387.558% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 3808.847% |
| Qrons Inc. | 351.42 Thousand USD | -2534.409% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -1357.573% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 78.366% |
| BioStem Technologies, Inc. | 4.47 Million USD | -107.021% |
| Skye Bioscience, Inc. | -5.72 Million USD | 261.814% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 45464.681% |
| Rebus Holdings, Inc. | 305 Thousand USD | -2935.418% |
| CSL Limited | 10.52 Billion USD | 99.912% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 78.685% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 54.34% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | -46500.01% |
| Adynxx, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | 5.64 Million USD | -63.906% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 41.267% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | -124.817% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -2203.856% |
| SQZ Biotechnologies Company | -36.23 Million USD | 125.548% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | -312.893% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | -898.508% |
| Mesoblast Limited | 55.85 Million USD | 83.426% |
| Marizyme, Inc. | 18.56 Million USD | 50.143% |
| Genus plc | 190.6 Million USD | 95.143% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | -314.075% |
| Pharming Group N.V. | 109.8 Million USD | 91.569% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | -976.213% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | -662.675% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | -1261.474% |
| ContraFect Corporation | -6.02 Million USD | 253.635% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | -6776.183% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | -701.263% |
| IMV Inc. | 7.67 Million USD | -20.696% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | -68.27% |
| MultiCell Technologies, Inc. | 90.04 USD | -10282023.501% |
| ONE Bio Corp. | 9.04 Million USD | -2.411% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 1361.349% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 28.487% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | -576.77% |
| Q BioMed Inc. | 4.06 Million USD | -128.03% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 69.699% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | -818.714% |
| Biomind Labs Inc. | 711.4 Thousand USD | -1201.377% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 84.709% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | -363.042% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 27.709% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -2473.747% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | -6522.145% |
| Curative Biotechnology, Inc. | 2.2 Million USD | -320.441% |
| GB Sciences, Inc. | 1.74 Million USD | -429.843% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 5137.339% |
| HST Global, Inc. | 96.79 Thousand USD | -9464.766% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | -4389.457% |
| Halberd Corporation | 144.72 Thousand USD | -6297.153% |
| Enzolytics Inc. | 981.65 Thousand USD | -843.103% |
| Agentix Corp. | 37.63 Thousand USD | -24502.121% |
| Resverlogix Corp. | 6.45 Million USD | -43.513% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 1475.453% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -2.02 Billion USD | 100.456% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 119.693% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | -30.93% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -241.799% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 204.73% |
| AVAX Technologies, Inc. | -5.9 Million USD | 256.83% |
| Zenith Capital Corp. | 10.06 Thousand USD | -91891.494% |
| Genscript Biotech Corporation | -1.06 Billion USD | 100.872% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | -4519.035% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | -288.009% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | -5527.67% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 50640.583% |
| Kadimastem Ltd | -253.1 Thousand USD | 3757.823% |
| Helix BioMedix, Inc. | -2.57 Million USD | 460.23% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | -4500.169% |
| LadRx Corporation | -2.03 Million USD | 554.612% |
| Cell Source, Inc. | 9.23 Million USD | -0.282% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -1357.573% |
| NovAccess Global Inc. | 2.17 Million USD | -324.979% |
| Affymax, Inc. | -5.59 Million USD | 265.41% |
| Itoco Inc. | 228.3 Thousand USD | -3955.112% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | -6707.921% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | -86.767% |
| Mobile Lads Corp. | 484.23 Thousand USD | -1811.898% |
| CytoDyn Inc. | 20.26 Million USD | 54.308% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | 1431015.611% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 99988.696% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | -20.14% |
| SYBLEU INC | 473.71 Thousand USD | -1854.349% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | -107.718% |
| International Stem Cell Corporation | 2.59 Million USD | -257.453% |
| Bioxytran, Inc. | 1.89 Million USD | -387.543% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -14733.487% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -324.505% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 3.43 Million USD | -169.599% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | -8.243% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 772.6 Thousand USD | -1098.284% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 840.642% |
| Neutra Corp. | 52.18 Thousand USD | -17640.096% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 471.958% |
| PureTech Health plc | -167.19 Million USD | 105.537% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 3880.205% |
| IXICO plc | -4.44 Million USD | 308.299% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 29.964% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 83.122% |
| CSL Limited | 10.52 Billion USD | 99.912% |
| Cellectis S.A. | -43.81 Million USD | 121.128% |